Figure 2.
csCIs of cardiovascular diseases for DLBCL survivors, Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated by levels of exposure to doxorubicin (N = 2600) and in the normal comparison group (N = 13 000) with non-cardiac death as a competing risk.

csCIs of cardiovascular diseases for DLBCL survivors, Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated by levels of exposure to doxorubicin (N = 2600) and in the normal comparison group (N = 13 000) with non-cardiac death as a competing risk.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal